About this trial
The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds normally found circulating in the blood. The nutrients (glucose, fructose, glutamine, acetate, and lactate) are also found in common foods. A nutrient tracer will be given to the participants through an intravenous (IV) catheter during surgery or biopsy, and blood will be collected every 30 minutes during the infusion to monitor safety parameters and the nutrient tracers. The investigators will collect a tissue sample after the completion of surgery. Participants not having an infusion will have their tissue collected after surgery or biopsy.
Participation in this study will not change patient care. All patients will receive standard of care treatment as determined by their doctors.
Eligibility criteria
Qualifiers
Patients must have radiographic evidence of known or probable kidney or urothelial cancer requiring surgical biopsy or excision.
Age ≥ 18 years
Subjects of all races and ethnic origins
The willingness to sign and ability to understand a written informed consent.
Disqualifiers
Uncontrolled or poorly controlled diabetes for patients receiving a 13C infusion
Pregnant or breastfeeding
Not a surgical candidate
Trial design
Treatments tested in this trial
- 13C-Glucose
- 13C-Acetate
- 13C-Lactate
- 13C-Glutamine
- 13C-Fructose
Treatment groups
Sponsors and collaborators
University of Texas Southwestern Medical Center
Lead sponsor
Howard Hughes Medical Institute
Collaborator
National Cancer Institute (NCI)
Collaborator